Search

Your search keyword '"M. Barr"' showing total 3,246 results

Search Constraints

Start Over You searched for: Author "M. Barr" Remove constraint Author: "M. Barr"
3,246 results on '"M. Barr"'

Search Results

1. Unlocking new contrast in a scanning helium microscope

2. List of Contributors

7. U-Pb zircon ages from metasedimentary and plutonic rocks in the Bras d'Or terrane of Cape Breton Island, Nova Scotia, Canada: insights into the Ediacaran–Cambrian tectonomagmatic evolution of Ganderia

8. Environmental Geology of Barite Deposits in Nevada

9. Precise U–Pb zircon dates from silicic super-eruptions during late Ediacaran extension in the Avalonian Caledonia terrane of southern New Brunswick, Canada

11. The Terreneuvian MacCodrum Brook section, Mira terrane, Cape Breton Island, Nova Scotia, Canada: age constraints from ash layers, organic-walled microfossils, and trace fossils

12. Using serial position effects to investigate memory dysfunction in homeless and precariously housed persons

13. P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

14. P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION

15. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia

16. Risk of kidney disease following a pregnancy complicated by diabetes: a longitudinal, population-based data-linkage study among Aboriginal women in the Northern Territory, Australia

18. Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary

19. Does My Driver Share My Moral View? Effects of Humanlikeness and Morality in an Adapted Trolley Problem

20. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

24. Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

27. Constraints on the age of Archaeozoon acadiense and evidence for hydrothermally transported zircon in the Ashburn Formation (Green Head Group), Saint John, New Brunswick, Canada

28. Measurement of the double-differential inclusive jet cross section in proton-proton collisions at s $$ \sqrt{s} $$ = 5.02 TeV

29. Tratamiento quirúrgico de las fracturas bifocales ipsilaterales de tibia: un reto para el cirujano

30. Model-independent search for pair production of new bosons decaying into muons in proton-proton collisions at s $$ \sqrt{s} $$ = 13 TeV

31. Measurement of boosted Higgs bosons produced via vector boson fusion or gluon fusion in the H → b b ¯ $$ \textrm{b}\overline{\textrm{b}} $$ decay mode using LHC proton-proton collision data at s $$ \sqrt{s} $$ = 13 TeV

32. Droughts of the early 19th century (1790–1830) in the northeastern Iberian Peninsula: integration of historical and instrumental data for high-resolution reconstructions of extreme events

34. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma

36. The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

37. A scoping review of psychiatric conditions associated with chronic pain in the homeless and marginally housed population

38. Using the Pugh Method to Select a Polymetallic Nodule Vertical Transport System

40. Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

41. Supplementary Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

42. Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

43. Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

44. Data from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

45. Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

46. Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

47. Cannabis use preferences in women with myofascial pelvic pain: A cross-sectional study

48. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

49. Petrology and age of the Lepreau River Dyke, southern New Brunswick, Canada: source of the end-Triassic Fundy Group basalts

50. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Catalog

Books, media, physical & digital resources